pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid has been researched along with Hyperplasia in 1 studies
pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid: a novel antagonist that selectively blocks P2 purinoceptor receptors; a useful tool to study co-transmission in tissues when ATP and coexisting neurotransmitters act in concert
5'-phosphopyridoxal-6-azobenzene-2,4-disulfonic acid : An arenesulfonic acid that is pyridoxal 5'-phosphate carrying an additional 2,4-disulfophenylazo substituent at position 6.
Hyperplasia: An increase in the number of cells in a tissue or organ without tumor formation. It differs from HYPERTROPHY, which is an increase in bulk without an increase in the number of cells.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Denda, M | 1 |
| Inoue, K | 1 |
| Fuziwara, S | 1 |
| Denda, S | 1 |
1 other study available for pyridoxal phosphate-6-azophenyl-2',4'-disulfonic acid and Hyperplasia
| Article | Year |
|---|---|
P2X purinergic receptor antagonist accelerates skin barrier repair and prevents epidermal hyperplasia induced by skin barrier disruption.
Topics: Adenosine Triphosphate; Animals; Antineoplastic Agents; Calcium; Cells, Cultured; Epidermis; Fluores | 2002 |